426 related articles for article (PubMed ID: 25396764)
1. Rationale for individualizing haemophilia care.
Sørensen B; Auerswald G; Benson G; Elezović I; Felder M; Lambert T; Morfini M; Remor E; Salaj P; Santagostino E; Šalek SZ; Ljung R
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):849-57. PubMed ID: 25396764
[TBL] [Abstract][Full Text] [Related]
2. Rapid rFVIIa enhanced on-demand dosing in haemophilia inhibitor patients.
Morfini M
Eur J Haematol; 2016 Feb; 96(2):111-8. PubMed ID: 26172449
[TBL] [Abstract][Full Text] [Related]
3. Preventing bleeds by treatment: new era for haemophilia changing the paradigm.
Marijke van den Berg H
Haemophilia; 2016 Jul; 22 Suppl 5():9-13. PubMed ID: 27405669
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors.
Antunes SV; Tangada S; Stasyshyn O; Mamonov V; Phillips J; Guzman-Becerra N; Grigorian A; Ewenstein B; Wong WY
Haemophilia; 2014 Jan; 20(1):65-72. PubMed ID: 23910578
[TBL] [Abstract][Full Text] [Related]
5. The current status of prophylactic replacement therapy in children and adults with haemophilia.
Ljung R; Gretenkort Andersson N
Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
[TBL] [Abstract][Full Text] [Related]
6. Current issues in prophylactic therapy for persons with hemophilia.
Dunn AL; Abshire TC
Acta Haematol; 2006; 115(3-4):162-71. PubMed ID: 16549891
[TBL] [Abstract][Full Text] [Related]
7. Considerations in individualizing prophylaxis in patients with haemophilia A.
Valentino LA
Haemophilia; 2014 Sep; 20(5):607-15. PubMed ID: 24712891
[TBL] [Abstract][Full Text] [Related]
8. Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25).
Meunier S; d'oiron R; Chambost H; Dolimier E; Guillet B;
Thromb Res; 2017 Mar; 151():17-22. PubMed ID: 28088606
[TBL] [Abstract][Full Text] [Related]
9. Haemophilia registries to complement clinical trial data: a pious hope or an urgent necessity?: Reflections on a possible way forward.
Keipert C; van den Berg HM; Keller-Stanislawski B; Hilger A
Haemophilia; 2016 Sep; 22(5):647-50. PubMed ID: 27397094
[No Abstract] [Full Text] [Related]
10. A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries.
Noone D; O'Mahony B; van Dijk JP; Prihodova L
Haemophilia; 2013 Jan; 19(1):44-50. PubMed ID: 22913831
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human prothrombin (MEDI8111) prevents bleeding in haemophilia A and B mice.
Hansson KM; Lindblom A; Elg M; Lövgren A
Haemophilia; 2016 May; 22(3):453-61. PubMed ID: 26635073
[TBL] [Abstract][Full Text] [Related]
12. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
Mahdi AJ; Obaji SG; Collins PW
Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
[TBL] [Abstract][Full Text] [Related]
13. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.
Collins P; Chalmers E; Chowdary P; Keeling D; Mathias M; O'Donnell J; Pasi KJ; Rangarajan S; Thomas A
Haemophilia; 2016 Jul; 22(4):487-98. PubMed ID: 27311929
[TBL] [Abstract][Full Text] [Related]
14. Patient powered prophylaxis: A 12-month study of individualized prophylaxis in adults with severe haemophilia A.
Sun HL; McIntosh KA; Squire SJ; Yang M; Bartholomew C; Gue DS; Camp PG; Jackson SC
Haemophilia; 2017 Nov; 23(6):877-883. PubMed ID: 28851133
[TBL] [Abstract][Full Text] [Related]
15. Personalized prophylaxis.
Collins PW
Haemophilia; 2012 Jul; 18 Suppl 4():131-5. PubMed ID: 22726096
[TBL] [Abstract][Full Text] [Related]
16. The past and future of haemophilia: diagnosis, treatments, and its complications.
Peyvandi F; Garagiola I; Young G
Lancet; 2016 Jul; 388(10040):187-97. PubMed ID: 26897598
[TBL] [Abstract][Full Text] [Related]
17. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
Dodd C; Watts RG
Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis in real life scenarios.
Fischer K; Konkle B; Broderick C; Kessler CM
Haemophilia; 2014 May; 20 Suppl 4():106-13. PubMed ID: 24762285
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia: A review of the literature.
Iorio A; Königs C; Reding MT; Rotellini D; Skinner MW; Mancuso ME; Berntorp E
Haemophilia; 2023 Jan; 29(1):33-44. PubMed ID: 36224704
[TBL] [Abstract][Full Text] [Related]
20. Defining severity of hemophilia: more than factor levels.
Pavlova A; Oldenburg J
Semin Thromb Hemost; 2013 Oct; 39(7):702-10. PubMed ID: 24026911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
